Cancer Market Research Reports & Industry Analysis

Highlights Comprehensive 565-page analysis of the Spanish tumor marker testing market. Major issues pertaining to the Spanish laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Mortality ...

Complete report $5,400. DataPack (test volumes, sales forecasts, supplier shares) $1,950. Highlights Comprehensive 575-page analysis of the UK tumor marker testing market. Major issues pertaining to the UK laboratory practice, as well as key economic, regulatory, demographic, social and technological ...

Complete report $8,700. DataPack (test volumes, sales forecasts, supplier shares) $3,450. Highlights Comprehensive 620-page analysis of the US tumor marker testing market. Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological ...

... Venture Planning Group contains 83 tables and provides analysis of the global tumor markers and special chemistry testing market, including emerging ... , such as specimen preparation devices, controls, calibrators and others. “2013 Tumor Markers and Special Chemistry Testing Market: US, Europe (France, Germany ...

Complete report $6,700. DataPack (test volumes, sales forecasts, supplier shares) $4,350. 2014 Analysis of the Argentinean Cancer Diagnostics Market is a new strategic ... the next five years. The report examines trends in the Argentinean cancer diagnostics market; reviews current and emerging tests; analyses ...

... test volumes, sales forecasts, supplier shares) $4,350. 2014 Analysis of Mexican Cancer Diagnostics Market is a new strategic analysis of the major business opportunities emerging in the Mexican cancer diagnostics market during the next five years. The report examines trends in the Mexico cancer diagnostics ...

... Pharma gives comprehensive insight on the various Monoclonal Antibodies being developed for the treatment of Cancer. Research report covers all the ... profile in development phase are covered in “Global Cancer Monoclonal Antibodies Pipeline Analysis” research report: Drug Profile Overview Alternate Names for ...

... the global prostate cancer market to grow from $3.5 billion in 2012 to $7.7 billion in 2017. Consensus Outlook: Prostate Cancer – Competition intensifies in race to the top analyses the global prostate cancer market players ... data analysis updates over the next 12 months Report Benefits: Consensus Outlook: Prostate Cancer – Competition intensifies in race to the top will allow you to: Evaluate future ...

... in the world, behind only heart disease. More people die from cancer every year around the world than AIDS, Tuberculosis and Malaria ... Cancer Test Market & Forecast Breast Cancer Test Market & Forecast Cervical Cancer Test Market & Forecast Colorectal (Colon) Cancer Test Market & Forecast Ovarian Cancer ...

... be done to improve how these predictive tools can be used? This week's Physician Views poll asks oncologists based in the US and 5EU markets: How many cancer patients they assess with a companion diagnostic prior to treatment? How the ...

The global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in ... clinical opinion This new KOL Insight report Colorectal Cancer - EGFR inhibitors on the verge of growth provides everyone interested in this dynamic cancer sector with a complete ...

... and development of small molecule and siRNA/miRNA inhibitors of the Pim Kinases. In addition, the report lists company-specific R&D pipelines of Pim Kinase inhibitors. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, ...

... of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of ... care (SoC) for relapsed and refractory MM pts. The report highlights the competition and commercial opportunity ...

... antibody inhibitors of the Wnt ligand or its receptors Frizzled and LRP5/6 in oncology. In addition, the report lists company-specific R&D pipelines of Wnt pathway inhibitors. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of ...

... has the largest share of the overall vaccines and specifically cancer vaccines market. This is followed by Europe and Asia. North America and ... process. Following parameters for each vaccine profile in development phase are covered in “Global Cancer Vaccines Pipeline Analysis” research report: Drug Profile ...

The present Competitive Intelligence report about Bruton’s Tyrosine Kinase (BTK) Inhibitorsprovides a competitor evaluation in the field of small molecule-based inhibitors of Bruton’s Tyrosine Kinase (BTK) for the treatment of B-cell related hematologic malign ancies and autoimmune diseases as of August 2013. ...

The present Competitive Intelligence report about Focal Adhesion Kinase (FAK) Inhibitors provides a competitor evaluation in the field of small molecule-based ... and development of selective and multi-target small molecule Focal Adhesion Kinase (FAK) inhibitors in oncology. In addition, the report lists company ...

... of the disease. During the next five years, the European cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. ... Recommendations Specific new product development opportunities with potentially significant market appeal during the next five years. Design criteria for ...

... alternative business expansion strategies for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological ... antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the French cancer diagnostics ...

... alternative business expansion strategies for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological ... antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the German cancer diagnostics ...

... alternative business expansion strategies for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological ... specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer ...

... alternative business expansion strategies for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological ... antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the Italian cancer diagnostics ...

... alternative business expansion strategies for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological ... specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the Japanese cancer ...

... alternative business expansion strategies for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological ... antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the Spanish cancer diagnostics ...

... alternative business expansion strategies for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological ... new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the UK cancer ...

... alternative business expansion strategies for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological ... new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the US cancer ...

... cells (CTCs) are believed to detach from primary or secondary tumors and enter the bloodstream, traveling to distant organs and forming new ... process of metastasis; however, their biology is still not entirely elucidated. Circulating tumor cells have tremendous utility in cancer research, aiding scientists ...

The present Competitive Intelligence report about Anaplastic Lymphoma Kinase (ALK) Inhibitors provides a competitor evaluation in the field of small molecule and antibody-based inhibitors of Anaplastic Lymphoma Kinase (ALK) for the treatment of solid tumors as of August 2013. Purchase ...

The present Competitive Intelligence report about Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors provides a competitor evaluation in the field of small molecule ... that repair DNA damage. Despite the recent failure of Sanofi’s PARP inhibitor iniparib, presentation of results from clinical studies with other ...

... when purchasing Hard Copy License depending on the location. “Ovarian Cancer Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ... reader to identify and understand the therapeutics associated with the Ovarian Cancer disease. The information for particular drug in development process ...

... purchasing Hard Copy License depending on the location. “Pancreatic Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ... . Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, ...

... and provides forecasts for 40 tumor markers by country and market segment, as well as sales and market shares for reagent and instrument suppliers. The report is available by region, country, section, market segment and individual test: Regions: Global, Europe Countries: France, Germany, Italy ...

... in the pipeline. According to RNCOS' report, "Cancer Monoclonal Antibodies Market Forecast to 2017", the market for cancer mAbs is estimated at US$ 24 Billion, and ... approval of these drugs will drive a major change in the market in terms of market share of current drugs. Finally, RNCOS concludes its report ...

... contains 450 tables from Venture Planning Group’s new 7-country study, “Tumor Markers: US, Europe, Japan,” including supplier shares, as well as test volume ... Japan Spain UK USA Market Segmentation Analysis Sales and market shares of major suppliers, by individual tumor marker and country. Five-year ...

... development and marketing strategies. Market Segmentation Analysis Sales and market shares of major suppliers, by individual tumor marker. Five-year test volume and sales forecasts for major tumor markers by market segment, including: Hospitals Commercial/Private Laboratories Physician Offices ...

... 320 tables from Venture Planning Group’s new 5-country study, “Tumor Markers in Europe: Market Segment Forecasts and Supplier Shares,” including supplier ... Germany Italy Spain UK Market Segmentation Analysis Sales and market shares of major suppliers, by individual tumor marker and country. Five-year ...

... growth. According to our latest research report “Cancer Generics Market Outlook 2017”, this market for cancer generics is expected to grow at 13%, reaching US$ 19 Billion ... oral and injectable options, encompassing all the recently approved generics along with existing ones. The detailed study of each drug ...

... new 7-country study, “Competing in the Global Cancer Diagnostics Market,” including supplier shares, as well as test volume and sales forecasts for 40 ... Coverage France Germany Italy Japan Spain UK USA Market Segmentation Analysis Sales and market shares of major suppliers, by individual tumor marker ...

... Venture Planning Group new report, “Competing in the US Cancer Diagnostics Market,” including supplier shares, as well as test volume and sales forecasts for ... strategies. Market Segmentation Analysis Sales and market shares of major suppliers, by individual tumor marker. Five-year test volume and sales ...

... Group new 5-country study, “Competing in the European Cancer Diagnostics Market,” including supplier shares, as well as test volume and sales forecasts for ... Spain UK Market Segmentation Analysis Sales and market shares of major suppliers, by individual tumor marker and country. Five-year test volume and ...

... potential market entrants identify and evaluate emerging opportunities in the European coagulation test market during the next five years, and assist ... Germany Italy Spain UK Sales and Market Share Analysis Sales and market shares of major coagulation testing instrument and reagent suppliers. Market ...

... potential market entrants identify and evaluate emerging opportunities in the global coagulation test market during the next five years, and assist industry ... Japan Spain UK USA Sales and Market Share Analysis Sales and market shares of major coagulation testing instrument and reagent suppliers. Market ...

... ‘malignant’ (potentially dangerous). ‘Breast cancer’ is a malignant tumor that has developed from cells in the breast. Typically breast cancer either begins in the cells ... over. The present report offers a comprehensive analysis of the global breast cancer diagnosis and treatment market with focus on regions ...

... and evaluates major business opportunities emerging in the cancer diagnostics market during the next five years; examines trends in France, Germany, ... diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading market players and potential entrants; and ...

... Comprehensive 585-page analysis of the French tumor marker testing market. Major issues pertaining to the French laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Mortality statistics and ...

... Comprehensive 570-page analysis of the Italian tumor marker testing market. Major issues pertaining to the Italian laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Mortality statistics and ...

... Comprehensive 585-page analysis of the German tumor marker testing market. Major issues pertaining to the German laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Mortality statistics and ...

... Comprehensive 590-page analysis of the Japanese tumor marker testing market. Major issues pertaining to the Japanese laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Mortality statistics and ...

... Comprehensive 565-page analysis of the Spanish tumor marker testing market. Major issues pertaining to the Spanish laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Mortality statistics and ...

... shares) $1,950. Highlights Comprehensive 575-page analysis of the UK tumor marker testing market. Major issues pertaining to the UK laboratory practice, as well as ... , lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. Ten-year test volume and sales forecasts over for ...